To include your compound in the COVID-19 Resource Center, submit it here.

IMO-2055: Development discontinued

Idera said Merck will not conduct further development of IMO-2055 to treat cancer after an increased incidence of neutropenia and electrolyte imbalances were reported in a Phase Ib trial of the compound in combination with cisplatin, 5-fluorouracil

Read the full 378 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE